Literature DB >> 6311867

Corticotropin-releasing factor test in normal subjects and patients with hypothalamic-pituitary-adrenal disorders.

M Nakahara, T Shibasaki, K Shizume, Y Kiyosawa, E Odagiri, T Suda, H Yamaguchi, T Tsushima, H Demura, T Maeda.   

Abstract

Corticotropin-releasing factor (CRF) tests were performed in normal subjects and patients with hypothalamic-pituitary-adrenal disorders. In normal subjects, after iv administration of 500 micrograms synthetic ovine CRF, plasma ACTH rose significantly to approximately 3.6 times the basal level at 30-60 min and cortisol reached a peak of 2.3 times the basal level at 60-90 min, whereas aldosterone peaked at 1.6 times the basal level at 60 min. Injection of 100 micrograms CRF in normal subjects also caused a significant increase in plasma ACTH and cortisol levels but only a slight increase in aldosterone. However, the total hormone released and their peak levels were lower than those elicited by the 500-microgram dosage. In patients with Cushing's disease, although the basal and peak levels of plasma ACTH and cortisol induced by administration of CRF were variable, the ratios of increase for the two hormones elicited by CRF were lower than those in normal subjects, especially for cortisol. In patients with Cushing's syndrome due to an adrenal adenoma, basal levels of ACTH were markedly suppressed and plasma ACTH and cortisol did not rise after CRF. In patients with isolated ACTH deficiency or Sheehan's syndrome the basal level of plasma ACTH was less than 5 pg/ml and no change in plasma ACTH occurred after injection of CRF. In patients with Nelson's syndrome or Addison's disease the basal levels of ACTH were extremely elevated but infusion of CRF increased plasma ACTH to even higher levels.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6311867     DOI: 10.1210/jcem-57-5-963

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Corticotropin releasing factor (CRF): diagnostic implications.

Authors:  O A Müller; G K Stalla; J Hartwimmer; J Schopohl; K von Werder
Journal:  Acta Neurochir (Wien)       Date:  1985       Impact factor: 2.216

2.  Plasma cortisol response cannot be classically conditioned in a taste-endocrine paradigm in humans.

Authors:  Liubov Petrakova; Karoline Boy; Marisa Kügler; Sven Benson; Harald Engler; Lars Möller; Manfred Schedlowski
Journal:  Psychopharmacology (Berl)       Date:  2017-08-13       Impact factor: 4.530

3.  Diagnosis of adrenal insufficiency.

Authors:  R N Clayton
Journal:  BMJ       Date:  1989-02-04

4.  The corticotropin-releasing factor test in the diagnosis of ectopic ACTH secretion.

Authors:  E Cagliero; M Lorenzi
Journal:  West J Med       Date:  1987-05

5.  Assessment of hypothalamic-pituitary-adrenal (HPA) axis dysfunction: comparison of ACTH stimulation, insulin-hypoglycemia and metyrapone.

Authors:  P I Hartzband; A J Van Herle; L Sorger; D Cope
Journal:  J Endocrinol Invest       Date:  1988-12       Impact factor: 4.256

6.  Idiopathic isolated ACTH deficiency and the response to CRF.

Authors:  K J Nowakowski; J R Tucci
Journal:  J Endocrinol Invest       Date:  1989-04       Impact factor: 4.256

7.  Corticotropin-releasing hormone (Crh) maps to mouse chromosome 3.

Authors:  L T Knapp; C E Keegan; A F Seasholtz; S A Camper
Journal:  Mamm Genome       Date:  1993       Impact factor: 2.957

8.  Corticotropin- and growth hormone-releasing factor (CRF and GRF) in the diagnosis of hypothalamo-pituitary diseases.

Authors:  K von Werder; O A Müller
Journal:  Neurosurg Rev       Date:  1985       Impact factor: 3.042

9.  Quadruple injection of hypothalamic peptides to evaluate pituitary function in normal subjects.

Authors:  K C Kaltenborn; W Jubiz
Journal:  West J Med       Date:  1985-01

Review 10.  Distinguishing Cushing's disease from the ectopic ACTH syndrome: Needles in a haystack or hiding in plain sight?

Authors:  Aimee R Hayes; Ashley B Grossman
Journal:  J Neuroendocrinol       Date:  2022-08-18       Impact factor: 3.870

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.